Functional biomarkers of musculoskeletal syndrome (MSS) for early in vivo screening of selective MMP-13 inhibitors

Journal of Pharmacological and Toxicological Methods

Volumn 64, Issue 1, 2011, Pages 89-96

  Mazurek, Suzanne G Nodop ^a   Li, Jun ^a   Nabozny, Gerald H ^a   Reinhart, Glenn A ^a   Muthukumarana, Akalushi C ^a   Harrison, Paul C ^a   Fryer, Ryan M ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Biomarker; Histology; Marimastat; Matrix metalloproteinase; Musculoskeletal syndrome; Rotarod

Indexed keywords

MARIMASTAT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; FIBROSIS; GROWTH PLATE; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL SYNDROME; NONHUMAN; ROTAROD TEST;

ANIMALS; BIOMARKERS, PHARMACOLOGICAL; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HYDROXAMIC ACIDS; JOINTS; LONGITUDINAL STUDIES; MALE; MATRIX METALLOPROTEINASE 13; MUSCULOSKELETAL DISEASES; MUSCULOSKELETAL SYSTEM; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 79961009626     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2011.02.002     Document Type: Article

References (17)

1. Chapillon P., Lalonde R., Jones N., Caston J. Early development of synchronized walking on the rotorod in rats: Effects of training and handling. Behavioral Brain Research 1997, 77-81.
2. Drummond A., Beckett P., Brown P., Bone E., Davidson A., Galloway W., et al. Preclinical and clinical studies of mmp inhibitors in cancer. Annals of New York Academy of Sciences 1999, 878:228-235.
3. Edwards P., Parker V. A simple, sensitive and objective method for early assessment of acrylamide neuropathy in rats. Toxicology and Applied Pharmacology 1977, 40(3):589-591.
4. Fernandez-Catalan C., Bode W., Huber R., Turk D., Calvete J.J., Lichte A., et al. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. The EMBO Journal 1998, 17:5238-5248.
5. Gruberg L., De Scheerder I. BRILLIANT-EU: Batimastat (BB94) Antirestenosis trial using the BiodivYsio local drug delivery PC-stent 2003, L L C Medscape.
6. Heath E.I., Grochow L.B. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs 2000, 59(5):1043-1055.
7. Krzeski P., Buckland-Wright C., Balint G., Clince G., Stoner K., Lyon R., et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Research & Therapy 2007, 9(R109):1-11.
8. Lindsey M mmP induction and inhibition in myocardial infarction. Heart Failure Reviews 2004, 9(1):7-19.
9. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: Biologic activity and clinical implications. Journal of Clinical Oncology 2000, 18(5):1135-1149.
10. Nemunaitis J., Poole C., Primrose J., Rosemurgy A., Malfetano J., Brown P., et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marmistat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies. Clinical Cancer Research 1998, 4(5):1101-1109.
11. Peterson J.T. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovascular Research 2006, 69(3):677-687.
12. Renkiewicz R., Qiu L., Lesch C., Sun X., Devalaraja R., Cody T., et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis and Rheumatism 2003, 48(6):1742-1749.
13. Schett G., Hayer S., Tohidast-Akrad M., Schmid B.J., Lang S., Turk B., et al. Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice. Arthritis and Rheumatism 2001, 44(12):2888-2898.
14. Thomas A., Steward W. Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opinion on Investigational Drugs 2009, 9(12):2913-2922.
15. van der Laan W.H., Quax P.H., Seemayer C.A., Huisman L.G., Pieterman E.J., Grimbergen J.M., et al. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Therapy 2003, 10:234-242.
16. Wojtowicz-Praga S., Torri J., Johnson M., Steen V., Marshall J., Ness E., et al. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. Journal of Clinical Oncology 1998, 16(6):2150-2156.
17. Zhou Z., Apte S., Soininen R., Cao R., Baaklini G., Rauser R., et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proceedings of the National Academy of Science 2000, 97(8):4052-4057.